Categories: Appointment

Dr Poonam Khetrapal Singh appointed Regional Director WHO South-East Asia for second term

Bengaluru, March 31, 2019: Dr Poonam Khetrapal Singh has been appointed Regional Director for World Health Organization South-East Asia, for a second five-year term.

The WHO Executive Board yesterday unanimously endorsed Dr Khetrapal Singh, who was earlier also unanimously nominated by 11 Member countries of the Region for another five years.

Congratulating her, WHO Director-General, Dr Tedros Adhanom Ghebreyesus, said, “the first woman to become Regional Director of WHO South-East Asia Region, you have provided dynamic leadership in a Region that accounts for a quarter of the world’s population but a disproportionate burden of diseases. Under your leadership, the Region has made remarkable progress.”

In her acceptance speech, Dr Khetrapal Singh said, “it is a privilege to once again be appointed as Regional Director of WHO South-East Asia Region. The confidence you have reposed in me is humbling.”

Outlining her vision for the second term that begins on 1 February 2019, Dr Khetrapal Singh, said sustaining the gains, accelerating progress to finish the unfinished agenda and innovating, would be the approach to ensure health and well being of the 1.8 billion people across the Region.

In her first term Dr Khetrapal Singh, focused on building an increasingly responsive and accountable WHO in the Region, while prioritizing persisting and emerging epidemiological and demographic challenges; promoting universal health coverage and building robust health systems; strengthening emergency risk management and articulating a strong regional voice in global health agenda.  She identified eight flagship priority programmes, focusing on results and accountability, which are cascading into sustainable and result-oriented efforts.

From vision to results

In the last five years, inclusive, sustainable and quantifiable gains have been made in the Region and are accelerating in pace every year.

Certified polio-free in 2014, WHO South-East Asia became the second WHO Region to eliminate maternal and neonatal tetanus in 2015. Four countries eliminated measles and six controlled rubella. Maternal and under-five deaths reduced significantly.

Thailand became the first in Asia-Pacific and the first with a large HIV epidemic—to eliminate mother-to-child transmission of HIV and syphilis. Maldives and Sri Lanka were certified malaria free. Maldives, Sri Lanka and Thailand eliminated lymphatic filariasis, India was declared yaws-free and Nepal trachoma-free.

For universal health coverage, access to safe, high-quality medicine is being enhanced through the South-East Asia Regulatory Network established in 2016. Countries have developed multi-sectoral action plans for a whole-of-society approach to reverse non-communicable diseases.

Prone to natural disasters, the Region’s investment in strengthening emergency risk management is evident from the responses to the Nepal earthquake, the Rohingya crisis in Bangladesh, cyclones, floods and earthquakes.

There is a strong political commitment to end TB by 2030.

Despite progress we have challenges; some permanent, some programmatic, some epidemiological and some transient, said Dr. Khetrapal Singh.

Sustain, accelerate and innovate

Detailing her vision for her next term in her acceptance speech at the Executive Board, Dr Khetrapal Singh said, “We must sustain the gains we made. It means ensuring we hold fast to our progress in diseases elimination, which history shows can return with a vengeance if attention falters, and ensuring that there is no room for complacency”.

“We must accelerate sustainable progress,” she said. Her eight regional flagship priority programmes are aligned to WHO’s global goals and health targets for Sustainable Development Goal 3.

“We must innovate”, Dr Khetrapal Singh said, adding innovation means taking advantage of the existing opportunities, being agile in applying research findings and developing new policies to meet the challenges we face.

“Ending TB will be difficult unless we develop and apply rapid diagnostics, which test and diagnose large populations in a short time. Likewise, we cannot hope to eradicate key neglected tropical diseases which largely affect the poor unless we can create and implement policies that address the needs of specific communities in specific areas,” she said.

The Regional Director said there is a robust commitment to leave no one behind. WHO’s ‘triple billion’ targets, the Sustainable Development Goal 3 and the efforts to achieve universal health coverage focus on equitable access and equity.

“I have confidence that together we will sustain our gains, accelerate progress and harness the full power of innovation to advance health and well-being across the WHO South-East Asia Region,” Dr Khetrapal Singh said.

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

17 hours ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

3 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

4 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

5 days ago

SpOvum® Launches ARTGPT Redefining Patient Support in Assisted Reproductive Technology (ART)

Launched for 1st time in India, ARTGPT is designed to address queries regarding A.R.T treatments Product created…

1 week ago